The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma
出版年份 2016 全文链接
标题
The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma
作者
关键词
-
出版物
Expert Opinion on Drug Discovery
Volume 12, Issue 2, Pages 225-235
出版商
Informa UK Limited
发表日期
2016-12-04
DOI
10.1080/17460441.2017.1268596
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy
- (2016) Jia Ruan et al. Current Hematologic Malignancy Reports
- Unknown
- (2016) AMERICAN JOURNAL OF HEMATOLOGY
- Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management
- (2015) Julie M. Vose AMERICAN JOURNAL OF HEMATOLOGY
- A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study
- (2015) Timothy S. Fenske et al. CANCER
- Treatment options for mantle cell lymphoma
- (2015) Piotr Smolewski et al. EXPERT OPINION ON PHARMACOTHERAPY
- Deubiquitinases (DUBs) and DUB inhibitors: a patent review
- (2015) Pershang Farshi et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- CD10-positive mantle cell lymphoma: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series
- (2015) Ariz Akhter et al. JOURNAL OF CLINICAL PATHOLOGY
- Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor
- (2015) S. Rosebeck et al. MOLECULAR CANCER THERAPEUTICS
- Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
- (2015) Tadeusz Robak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-specific signaling to p53 is mimicked by Mdm2 inactivation in zebrafish: insights from mdm2 and mdm4 mutant zebrafish
- (2015) J S Chua et al. ONCOGENE
- Deubiquitinase inhibition as a cancer therapeutic strategy
- (2015) Padraig D'Arcy et al. PHARMACOLOGY & THERAPEUTICS
- Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib
- (2015) Ling Peng et al. SUPPORTIVE CARE IN CANCER
- Putative E3 Ubiquitin Ligase of Human Rotavirus Inhibits NF-κB Activation by Using Molecular Mimicry To Target β-TrCP
- (2015) Marco Morelli et al. mBio
- Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma
- (2015) Violetta V. Leshchenko et al. Oncotarget
- Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance
- (2015) Areumnuri Kim et al. Oncotarget
- Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
- (2015) Ling-Ling Zhao et al. Cancer Medicine
- RNF115/BCA2 E3 Ubiquitin Ligase Promotes Breast Cancer Cell Proliferation through Targeting p21Waf1/Cip1 for Ubiquitin-Mediated Degradation
- (2015) Zehua Wang et al. NEOPLASIA
- The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells
- (2014) J. Zhang et al. BLOOD
- Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
- (2014) Michael Wang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Emerging Potential of Therapeutic Targeting of Ubiquitin-Specific Proteases in the Treatment of Cancer
- (2014) A. Pal et al. CANCER RESEARCH
- Histone H2B monoubiquitination: roles to play in human malignancy
- (2014) Alexander J Cole et al. ENDOCRINE-RELATED CANCER
- Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)
- (2014) Vicki A. Morrison et al. LEUKEMIA & LYMPHOMA
- Cullin 4A and 4B ubiquitin ligases interact with γ-tubulin and induce its polyubiquitination
- (2014) Anand Thirunavukarasou et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Regulation of proteolysis by human deubiquitinating enzymes
- (2013) Ziad M. Eletr et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Targeting the ubiquitin–proteasome system for cancer therapy
- (2013) Min Shen et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
- (2013) Rami Rahal et al. NATURE MEDICINE
- Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells
- (2013) Sabrina Manni et al. PLoS One
- Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
- (2013) S. Bea et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities
- (2012) H. J. Jung et al. BLOOD
- Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features
- (2012) A. Navarro et al. CANCER RESEARCH
- Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma
- (2012) S. Xargay-Torrent et al. CLINICAL CANCER RESEARCH
- Molecular pathogenesis of mantle cell lymphoma
- (2012) Pedro Jares et al. JOURNAL OF CLINICAL INVESTIGATION
- The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
- (2012) Areumnuri Kim et al. LEUKEMIA RESEARCH
- Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA
- (2012) R. J. Jones et al. MOLECULAR CANCER THERAPEUTICS
- Blocking Autophagy Prevents Bortezomib-Induced NF-κB Activation by Reducing I-κBα Degradation in Lymphoma Cells
- (2012) Li Jia et al. PLoS One
- The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
- (2011) J. W. Friedberg et al. BLOOD
- Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
- (2011) R. Kridel et al. BLOOD
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
- (2011) D. Chen et al. CURRENT CANCER DRUG TARGETS
- Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma
- (2011) Hyun Joo Jung et al. EXPERIMENTAL HEMATOLOGY
- Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group
- (2011) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Proteasome Inhibitors to Overcome Bortezomib Resistance
- (2011) Amy M. Ruschak et al. JNCI-Journal of the National Cancer Institute
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
- (2011) C. Tom Kouroukis et al. LEUKEMIA & LYMPHOMA
- Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress, and induces caspase-dependent cell death in antiestrogen–sensitive and resistant ER+ breast cancer cells
- (2010) Sudharsan Periyasamy-Thandavan et al. Autophagy
- The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78
- (2010) G. Roue et al. BLOOD
- Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
- (2010) P. Perez-Galan et al. BLOOD
- Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma
- (2010) Jorge E. Romaguera et al. BRITISH JOURNAL OF HAEMATOLOGY
- Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia
- (2010) Agathoclis Agathocleous et al. BRITISH JOURNAL OF HAEMATOLOGY
- Time to Treatment Response in Patients with Follicular Lymphoma Treated with Bortezomib Is Longer Compared with Other Histologic Subtypes
- (2010) O. A. O'Connor et al. CLINICAL CANCER RESEARCH
- Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma
- (2010) Lapo Alinari et al. mAbs
- PRDM1 Is Required for Mantle Cell Lymphoma Response to Bortezomib
- (2010) S. Desai et al. MOLECULAR CANCER RESEARCH
- Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo: Therapeutic Implications
- (2010) L. V. Pham et al. MOLECULAR CANCER THERAPEUTICS
- Gene expression profiling in lymphoma diagnosis and management
- (2009) Javeed Iqbal et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma
- (2009) N. Di Bella et al. BLOOD
- Fludarabine, Bortezomib, Myocet®and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma
- (2009) Enrico Orciuolo et al. BRITISH JOURNAL OF HAEMATOLOGY
- The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins
- (2009) Sjoerd J. L. van Wijk et al. FASEB JOURNAL
- A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study
- (2009) Oliver Weigert et al. LEUKEMIA & LYMPHOMA
- Ubiquitinated Proteins Activate the Proteasome by Binding to Usp14/Ubp6, which Causes 20S Gate Opening
- (2009) Andreas Peth et al. MOLECULAR CELL
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes
- (2008) V. K. Prasad et al. BLOOD
- Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways
- (2008) Edgar Gil Rizzatti et al. LEUKEMIA & LYMPHOMA
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now